Neuronetics, Inc.

NASDAQ:STIM

Medical - Diagnostics & Research

Healthcare
$1.25 +0.31%

+$0.00 today

Market cap
$97.16M
Beta
1.04
P/E (TTM)
-2.3
EPS (TTM)
-$0.53
52W Low $0.80High $4.85

Volume 2.55M

Average 2.44M

STIM Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Neuronetics, Inc.NASDAQ: STIM

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $1.36M fell 15.6% year over year, ahead of the -47.4% change in trailing-twelve-month research & development. Sequentially, it fell 18.1% from the prior quarter. Over 3 fiscal years it compounded at -11.0% a year.

Context

  • Research & development amounted to 4.4% of revenue in FY2025, down 12.6 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -15.6% holds above the trailing-twelve-month pace of -47.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.36M-18.1% QoQ
Last fiscal yearDec 2025
$6.58M-48.4% YoY
LTMMar 2026
$6.33M-47.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-15.6%——
1 year-48.4%——
3-year CAGR-11.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
6.58M USD
Year-over-year change
-48.4%
4-year CAGR
-4.5%

Research & Development vs competitors

How STIM compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -47.4% is the 8th highest of 9, against a peer median of +5.4%.
  • Research & development amounts to 4.2% of revenue for STIM, versus a peer median of 112.1%.
STIM Competitors
Research & Development for STIM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$113.23M USD+11.4%-23.3%327.7%
CATXPerspective Therapeutics, Inc.LTM Mar 2026$85.68M USD+76.6%+218.7%13864.6%
CDXSCodexis, Inc.LTM Mar 2026$47.7M USD-0.5%-13.2%61.1%
OSUROraSure Technologies, Inc.LTM Mar 2026$46.23M USD+68.7%+5.5%40.9%
OABIOmniAb, Inc.LTM Mar 2026$44.75M USD-15.8%-0.4%154.8%
NYXHNyxoah S.A.LTM Mar 2026€42.56M EUR+17.3%+39.2%260.8%
PROFProfound Medical Corp.LTM Mar 2026$21.15M USD-1.0%+12.6%112.1%
STIMNeuronetics, Inc.LTM Mar 2026$6.33M USD-47.4%-11.0%4.2%
PREPrenetics Global LimitedLTM Mar 2026$4.57M USD-56.9%-5.0%4.0%
ATLNAtlantic International Corp.LTM Dec 2025$0 USD——0.0%
Peer median (excluding STIM) —+5.4%+2.5%112.1%

Competitors are the stored peer set for STIM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue55.31M65.21M71.35M74.89M149.16M
Cost of Revenue11.65M15.48M19.64M20.73M76.85M
Gross Profit43.66M49.72M51.71M54.16M72.31M
Gross Margin78.9%76.3%72.5%72.3%48.5%
Research & Development7.92M9.34M9.52M12.77M6.58M
Selling, General & Admin63.3M75.5M72.74M75.95M97.16M
Operating Expenses71.22M84.83M82.26M88.72M103.74M
Depreciation & Amortization1.06M1.65M2.01M2.07M3.47M
EBITDA(26.81M)(31.96M)(22.76M)(34.37M)(27.12M)
EBITDA Margin-48.5%-49.0%-31.9%-45.9%-18.2%
Operating Income(27.56M)(35.11M)(30.55M)(34.56M)(31.44M)
Operating Margin-49.8%-53.8%-42.8%-46.2%-21.1%
Interest Income0024K00
Interest Expense3.3M3.6M5.42M7.29M8.42M
Other Income / Expenses(3.61M)(2.1M)365K(9.18M)(7.56M)
Income Before Tax(31.17M)(37.21M)(30.19M)(43.74M)(39M)
Pre-Tax Margin-56.4%-57.1%-42.3%-58.4%-26.1%
Income Tax Expense00(24K)(14K)0
Net Income(31.19M)(37.16M)(30.19M)(43.71M)(39M)
Net Margin-56.4%-57.0%-42.3%-58.4%-26.1%
EPS (Basic)(1.22)(1.38)(1.05)(1.38)(0.59)
EPS (Diluted)(1.22)(1.38)(1.05)(1.38)(0.59)
Weighted Avg Shares25.48M26.9M28.66M31.73M65.95M
Weighted Avg Shares (Diluted)25.48M26.9M28.66M31.73M65.95M

Neuronetics, Inc.

NASDAQ:STIM

Intrinsic Alpha fair value

Locked

Current Price

$1.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.